Subject:
- Active Substance: Spesolimab
- Name: Spevigo®
- Therapeutic area: Generalized pustular psoriasis (GPP)
- Pharmaceutical company: Boehringer Ingelheim Pharma GmbH & Co. KG
Time table:
- Start: 01.02.2023
- Final decision by G-BA: 20.07.2023
Final decision:
- No additional benefit proved